Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.
Malin BoremalmA JutoM AxelssonL NovakovaT FrisellAnders SvenningssonJan N LyckeF PiehlJ SalzerPublished in: European journal of neurology (2019)
In patients with RRMS on interferon/glatiramer acetate with breakthrough disease, switching to NTZ or RTX was associated with less disease activity compared with FGL. RTX displayed superior medication persistence compared with both NTZ and FGL.
Keyphrases
- multiple sclerosis
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- white matter
- diffuse large b cell lymphoma
- healthcare
- dendritic cells
- open label
- adverse drug
- hodgkin lymphoma
- chronic lymphocytic leukemia
- emergency department
- stem cells
- randomized controlled trial
- clinical trial
- mesenchymal stem cells
- smoking cessation
- study protocol